{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:51:12Z","timestamp":1790664672108,"version":"4.1.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Switching to dolutegravir\/lamivudine (DTG\/3TC) was noninferior to continuing tenofovir alafenamide (TAF)\u2013based regimens for maintaining virologic suppression at week 48 of the TANGO study. Here we present week 144 outcomes (efficacy, safety, weight, and biomarkers).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>TANGO is a randomized (1:1, stratified by baseline third agent class), open-label, noninferiority phase 3 study. Virologically suppressed (&amp;gt;6 months) adults with human immunodeficiency virus type 1 (HIV-1) switched to once-daily DTG\/3TC or continued TAF-based regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 741 participants received study treatment (DTG\/3TC, n\u2005=\u2005369; TAF-based regimen, n\u2005=\u2005372). At week 144, the proportion of participants with an HIV-1 RNA level \u226550 copies\/mL (primary end point, Snapshot; intention-to-treat\u2013exposed population) after switching to DTG\/3TC was 0.3% (1 of 369) versus 1.3% (5 of 372) for those continuing TAF-based regimens, demonstrating noninferiority (adjusted treatment difference, \u22121.1 [95% confidence interval, \u22122.4 to .2), with DTG\/3TC favored in the per-protocol analysis (adjusted treatment difference, \u22121.1 [\u22122.3 to \u2212.0]; P\u2005=\u2005.04). Few participants met confirmed virologic withdrawal criteria (none in the DTG\/3TC and 3 in the TAF-based regimen group), with no resistance observed. Drug-related adverse events were more frequent with DTG\/3TC (15%; leading to discontinuation in 4%) than TAF-based regimens (5%; leading to discontinuation in 1%) through week 144, but rates were comparable after week 48 (4%; leading to discontinuation in 1% in both groups). Changes from baseline in lipid values generally favored DTG\/3TC; no clinical impact on renal function and comparable changes in inflammatory and bone biomarkers across groups were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Switching to DTG\/3TC demonstrated noninferior and durable efficacy compared with continuing TAF-based regimens in treatment-experienced adults with HIV-1, with good safety and tolerability, and no resistance through 144 weeks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciac036","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T15:13:02Z","timestamp":1643037182000},"page":"975-986","source":"Crossref","is-referenced-by-count":143,"title":["Efficacy and Safety of Switching to Dolutegravir\/Lamivudine Versus Continuing a Tenofovir Alafenamide\u2013Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial"],"prefix":"10.1093","volume":"75","author":[{"given":"Olayemi","family":"Osiyemi","sequence":"first","affiliation":[{"name":"Triple O Research Institute PA , West Palm Beach, Florida , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"De Wit","sequence":"additional","affiliation":[{"name":"CHU Saint-Pierre, Universit\u00e9 Libre de Bruxelles , Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fa\u00efza","family":"Ajana","sequence":"additional","affiliation":[{"name":"Centre Hospitalier de Tourcoing , Tourcoing , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Bisshop","sequence":"additional","affiliation":[{"name":"Holdsworth House Medical Brisbane , Queensland , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Portilla","sequence":"additional","affiliation":[{"name":"Hospital General Universitario de Alicante , Alicante , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Pierre","family":"Routy","sequence":"additional","affiliation":[{"name":"McGill University Health Centre , Montreal, Quebec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wyen","sequence":"additional","affiliation":[{"name":"Praxis am Ebertplatz , Cologne , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounir","family":"Ait-Khaled","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Brentford , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Leone","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Research Triangle Park, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A","family":"Pappa","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Research Triangle Park, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruolan","family":"Wang","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Research Triangle Park, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Wright","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline , Brentford , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"George","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline , Bangalore , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Wynne","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Research Triangle Park, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Aboud","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Brentford , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"van Wyk","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Brentford , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly Y","family":"Smith","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Research Triangle Park, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,25]]},"reference":[{"key":"2022092921012658900_CIT0001","doi-asserted-by":"crossref","first-page":"113","DOI":"10.18683\/germs.2017.1115","article-title":"2-Drug regimens in HIV treatment: pharmacological considerations.","volume":"7","author":"Back","year":"2017","journal-title":"Germs"},{"key":"2022092921012658900_CIT0002","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society\u2013USA Panel.","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"key":"2022092921012658900_CIT0003","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAD.0000000000003070","article-title":"Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy-naive adults with HIV-1 infection.","volume":"36","author":"Cahn","year":"2022","journal-title":"AIDS"},{"key":"2022092921012658900_CIT0004","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"2022092921012658900_CIT0005","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","article-title":"Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment\u2013naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials.","volume":"83","author":"Cahn","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022092921012658900_CIT0006","article-title":"EACS guidelines version 11.0","author":"European AIDS Clinical Society."},{"key":"2022092921012658900_CIT0007","article-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents."},{"key":"2022092921012658900_CIT0008","first-page":"72","volume-title":"Program and abstracts of the 11th IAS Conference on HIV Science (virtual)","author":"Llibre","year":"2021"},{"key":"2022092921012658900_CIT0009","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide\u2013based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study.","volume":"71","author":"van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022092921012658900_CIT0010","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/hiv.13050","article-title":"Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence.","volume":"22","author":"Punekar","year":"2021","journal-title":"HIV Med"},{"key":"2022092921012658900_CIT0011","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s40121-021-00522-7","article-title":"HIV treatment with the two-drug regimen dolutegravir plus lamivudine in real-world clinical practice: a systematic literature review.","volume":"10","author":"Patel","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2022092921012658900_CIT0012","first-page":"152","volume-title":"Program and abstracts of the 28th Conference on Retroviruses and Opportunistic Infections (virtual)","author":"Benson","year":"2021"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac036\/43398326\/ciac036.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/6\/975\/46205189\/ciac036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/6\/975\/46205189\/ciac036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T17:07:32Z","timestamp":1664471252000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/75\/6\/975\/6515475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":12,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,1,25]]},"published-print":{"date-parts":[[2022,9,29]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac036","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,15]]},"published":{"date-parts":[[2022,1,25]]}}}